Quince Therapeutics Inc.
13F holders, Q4 2024 (December 31)35holders +2
7new positions
7sold out
1famous investor
$1.87avg. 13F price*
At the end of Q4 2024, 35 institutions reported holding Quince Therapeutics Inc. in their 13F filings, up 2 from Q3 2024. 7 opened new positions and 7 sold out. The largest holders were Vanguard Group Inc. ($2.4M), EPIQ Capital Group, LLC ($1.5M) and Renaissance Technologies ($978K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Quince Therapeutics Inc.
- CUSIP
- 22053A107
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $417K |
| Exits | 7 | $464K |
All 13F filers, Q3 2024 → Q4 2024: 685,233 shares bought and 770,206 shares sold, net −84,973 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 35 holders
| Vanguard Group Inc. | 0.00% | Add +6.1% | 1,272,340 | $2.4M |
| EPIQ Capital Group, LLC | 0.40% | Reduce -0.1% | 824,782 | $1.5M |
| Renaissance Technologies | 0.00% | Add +0.1% | 523,050 | $978K |
| BlackRock, Inc. | 0.00% | Add +24.9% | 447,733 | $837K |
| Geode Capital Management, LLC | 0.00% | Add +10.8% | 375,932 | $703K |
| HighTower Advisors, LLC | 0.00% | No change | 341,570 | $639K |
| Shay Capital LLC | 0.13% | Add +60.8% | 276,799 | $518K |
| Alphabet Inc. | 0.02% | No change | 189,122 | $354K |
| ADAR1 Capital Management, LLC | 0.06% | No change | 142,958 | $267K |
| State Street Corp. | 0.00% | Add +120.7% | 124,911 | $234K |
| Mariner, LLC | 0.00% | No change | 122,461 | $229K |
| Bridgeway Capital Management, LLC | 0.00% | Add +4.3% | 92,317 | $173K |
| Scharf Investments, LLC | 0.01% | New | 91,061 | $170K |
| Morgan Stanley | 0.00% | Add +800.0% | 76,701 | $143K |
| Northern Trust Corp. | 0.00% | Add +48.5% | 50,524 | $94K |
| Two Sigma Investments, LP | 0.00% | New | 30,341 | $57K |
| Virtu Financial LLC | 0.00% | New | 29,204 | $55K |
| Anfield Capital Management, LLC | 0.02% | New | 26,656 | $50K |
| HRT Financial LP | 0.00% | New | 20,232 | $37K |
| Kestra Advisory Services, LLC | 0.00% | New | 15,359 | $29K |
| Nixon Peabody Trust Co. | 0.00% | No change | 11,126 | $21K |
| Jane Street Group, LLC | 0.00% | New | 10,475 | $20K |
| Citigroup Inc. | 0.00% | Reduce -69.8% | 5,165 | $10K |
| Bank of America Corp. | 0.00% | Reduce -98.1% | 3,029 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -69.4% | 1,697 | $3K |
| UBS Group AG | 0.00% | Add +132.1% | 1,114 | $2K |
| Osaic Holdings, Inc. | 0.00% | Add +182.3% | 782 | $1K |
| JPMorgan Chase & Co. | 0.00% | Reduce -0.6% | 545 | $1K |
| JDM Financial Group LLC | 0.00% | No change | 340 | $636 |
| Parallel Advisors, LLC | 0.00% | No change | 295 | $552 |
| Hurley Capital, LLC | 0.00% | — | 121 | $236 |
| Financial Avengers, Inc. | 0.00% | No change | 100 | $187 |
| Barclays PLC | 0.00% | No change | 100 | $187 |
| Westside Investment Management, Inc. | 0.00% | No change | 75 | $140 |
| SBI Securities Co., Ltd. | 0.00% | — | 74 | $138 |
"% of holder's portfolio" is QUINCE THERAPEUTICS INC's weight in each manager's 13F, not the share of Quince Therapeutics Inc. the manager owns.